Thousands tracked in psoriasis drug safety study

NCT ID NCT02786186

First seen Feb 20, 2026 · Last updated May 12, 2026 · Updated 14 times

Summary

This study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective the drug secukinumab is in everyday use. Researchers recorded side effects and how well the treatment cleared skin symptoms. The goal was to gather real-world evidence, not to test a new cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Edmonton, Alberta, T6G 1C3, Canada

  • Novartis Investigative Site

    Nanaimo, British Columbia, V9T 1W1, Canada

  • Novartis Investigative Site

    Surrey, British Columbia, V3R 6A7, Canada

  • Novartis Investigative Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Novartis Investigative Site

    Brandon, Manitoba, R7A 0L5, Canada

  • Novartis Investigative Site

    Winnepeg, Manitoba, R3M1Z9, Canada

  • Novartis Investigative Site

    Winnipeg, Manitoba, R3C 0N2, Canada

  • Novartis Investigative Site

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1A 4Y3, Canada

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1C 2H5, Canada

  • Novartis Investigative Site

    Hamilton, Ontario, L8N 3Z5, Canada

  • Novartis Investigative Site

    London, Ontario, N6A 3H7, Canada

  • Novartis Investigative Site

    Nepean, Ontario, K2G 6E2, Canada

Conditions

Explore the condition pages connected to this study.